Effect of sodium–glucose co-transporter-2 inhibitors on the levels of serum asprosin in patients with newly diagnosed type 2 diabetes mellitus

The plasma levels of atrial natriuretic peptide and brain natriuretic peptide in type 2 diabetes treated with sodium-glucose cotransporter-2 inhibitor

(2020) Xiu Feng et al.   ANNALES D ENDOCRINOLOGIE

The role of Asprosin in patients with dilated cardiomyopathy

(2020) Ming-Shien Wen et al.   BMC Cardiovascular Disorders

Expression of asprosin in rat hepatic, renal, heart, gastric, testicular and brain tissues and its changes in a streptozotocin-induced diabetes mellitus model

(2020) Nevin Kocaman et al.   TISSUE & CELL

Attenuation of weight loss through improved antilipolytic effect in adipose tissue via the SGLT2 inhibitor tofogliflozin

(2019) Akihiro Yoshida et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Asprosin improves the survival of mesenchymal stromal cells in myocardial infarction by inhibiting apoptosis via the activated ERK1/2-SOD2 pathway

(2019) Zhengbin Zhang et al.   LIFE SCIENCES

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

(2019) John J.V. McMurray et al.   NEW ENGLAND JOURNAL OF MEDICINE

Sodium Glucose Cotransporter-2 Inhibition and Cardiorenal Protection

(2019) David Z. Cherney et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Increased serum level and impaired response to glucose fluctuation of asprosin is associated with type 2 diabetes mellitus

(2019) Xinyue Zhang et al.   Journal of Diabetes Investigation

10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2020

(2019)   DIABETES CARE

A novel biochemical marker for predicting the severity of ACS with unstable angina pectoris: Asprosin

(2018) Ahmet Cagdas Acara et al.   AMERICAN JOURNAL OF EMERGENCY MEDICINE

Long-term efficacy and safety of ertugliflozin monotherapy in patients with inadequately controlled T2DM despite diet and exercise: VERTIS MONO extension study

(2018) Ronnie Aronson et al.   DIABETES OBESITY & METABOLISM

Do sodium-glucose co-transporter-2 inhibitors prevent heart failure with a preserved ejection fraction by counterbalancing the effects of leptin? A novel hypothesis

(2018) Milton Packer   DIABETES OBESITY & METABOLISM

IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045

(2018) N.H. Cho et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetes

(2018) W. Timothy Garvey et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Asprosin is a centrally acting orexigenic hormone

(2017) Clemens Duerrschmid et al.   NATURE MEDICINE

The Association Between the Dosage of SGLT2 Inhibitor and Weight Reduction in Type 2 Diabetes Patients: A Meta-Analysis

(2017) Xiaoling Cai et al.   Obesity

SGLT2 Inhibition by Empagliflozin Promotes Fat Utilization and Browning and Attenuates Inflammation and Insulin Resistance by Polarizing M2 Macrophages in Diet-induced Obese Mice

(2017) Liang Xu et al.   EBioMedicine

Circulating asprosin concentrations are increased in type 2 diabetes mellitus and independently associated with fasting glucose and triglyceride

(2017) Lei Zhang et al.   CLINICA CHIMICA ACTA

Asprosin, a Fasting-Induced Glucogenic Protein Hormone

(2016) Chase Romere et al.   CELL

Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus

(2016) Hiddo J.L. Heerspink et al.   CIRCULATION

Sodium-glucose co-transporter-2 inhibitors suppress atrial natriuretic peptide secretion in patients with newly diagnosed Type 2 diabetes

(2016) Y. Wang et al.   DIABETIC MEDICINE

The Mechanisms and Therapeutic Potential of SGLT2 Inhibitors in Diabetes Mellitus

(2015) Volker Vallon   Annual Review of Medicine

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

(2015) Bernard Zinman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Adipokines in health and disease

(2015) Mathias Fasshauer et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial

(2013) William T Cefalu et al.   LANCET

Effects of Dapagliflozin, an SGLT2 Inhibitor, on HbA1c, Body Weight, and Hypoglycemia Risk in Patients With Type 2 Diabetes Inadequately Controlled on Pioglitazone Monotherapy

(2012) J. Rosenstock et al.   DIABETES CARE

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial

(2010) Clifford J Bailey et al.   LANCET